🟢 Summit Therapeutics is trading 11% up today as broader markets recover

Summit Therapeutics is trading 10.50% up at $15.68, with the broader market recovery the clearest explanation for the move.

• The stock rebounded after its 12.24% decline on November 5; Nasdaq rose 1.66% and S&P 500 rose 0.86% amid improved sentiment after a stronger-than-expected October jobs report.
• Q3 results and AstraZeneca’s investment are relevant background, but reporting identifies no new company-specific announcement on November 6 as the cause.
• The FDA’s ivonescimab decision is expected November 14.